Annals of Allergy, Asthma & Immunology 1996-05-01

Efficacy of acrivastine plus pseudoephedrine for symptomatic relief of seasonal allergic rhinitis due to mountain cedar.

B O Williams, H Hull, P McSorley, M F Frosolono, R L Sanders

Index: Ann. Allergy Asthma Immunol. 76(5) , 432-8, (1996)

Full Text: HTML

Abstract

Acrivastine is a second-generation H1-antagonist chemically related to triprolidine, but more polar and with less central nervous system penetration than triprolidine.The efficacy of the antihistamine-decongestant combination product (Semprex-D capsules) containing acrivastine 8 mg plus pseudoephedrine HCl 60 mg was evaluated for the treatment of seasonal allergic rhinitis symptoms.A total of 676 patients sensitive to mountain cedar pollen was enrolled into a 6-center, randomized, double-blind, placebo-controlled, parallel, 4-group study designed to compare acrivastine + pseudoephedrine, acrivastine, pseudoephedrine, and placebo. Patients with demonstrable diary symptom scores at baseline took study medication (4 doses/day) and recorded symptom scores twice daily for 2 weeks. The effectiveness of the acrivastine + pseudoephedrine combination was examined relative to the individual components and placebo in terms of changes in diary symptom scores.Over the 2-week period, the combination of acrivastine plus pseudoephedrine was significantly more effective than (1) acrivastine, pseudoephedrine, and placebo (P < .001) for relief of all symptoms; (2) pseudoephedrine (P < .001) for relieving allergy symptoms, ie, running nose, sneezing, itchy nose/throat and tearing; and (3) acrivastine (P < .001) for reducing nasal congestion. Relative to placebo, small increases in adverse experience rates were observed with acrivastine + pseudoephedrine for dry mouth, insomnia, somnolence, and headache.These findings in a large clinical trial demonstrate (1) the efficacy of acrivastine and (2) that each component of the combination of acrivastine 8 mg plus pseudoephedrine HCl 60 mg contributes to the overall efficacy, thereby supporting the conclusion that the combination is rational, safe, and effective for the treatment of allergic rhinitis.


Related Compounds

Related Articles:

Identification of novel functional inhibitors of acid sphingomyelinase.

2011-01-01

[PLoS ONE 6 , e23852, (2011)]

Simultaneous analysis of the H1-antihistamine acrivastine and the decongestant pseudoephedrine hydrochloride by high-performance liquid chromatography.

2005-04-01

[J. Pharm. Biomed. Anal. 37(4) , 663-7, (2005)]

Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge.

2000-04-01

[Ann. Allergy Asthma Immunol. 84(4) , 451-9, (2000)]

Quantification of antihistamine acrivastine in plasma by solid-phase extraction and high-performance liquid chromatography.

2007-01-04

[J. Pharm. Biomed. Anal. 43(1) , 293-7, (2007)]

Evaluation and comparison of five matrix excipients for the controlled release of acrivastine and pseudoephedrine.

2004-01-01

[Drug Dev. Ind. Pharm. 30(10) , 1009-17, (2004)]

More Articles...